No headlines found.
Palatin Reports Fiscal Year 2026 Financial Results and Provides Business Update
PRNewswire (Mon, 28-Sep 7:31 AM ET)
Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor (MCR) system. Its product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical need and commercial potential. It is also developing, dependent on resources for development activities, MC1R agonist products, with potential to treat inflammatory and autoimmune diseases, such as dry eye disease, which is also known as keratoconjunctivitis sicca, uveitis, diabetic retinopathy, and inflammatory bowel disease. It has one operating segment life science.
Palatin Technologies trades on the NASDAQ stock market under the symbol PTN.
As of October 9, 2026, PTN stock price declined to $8.60 with 31,325 million shares trading.
PTN has a beta of -1.44, meaning it tends to be less sensitive to market movements. PTN has a correlation of 0.02 to the broad based SPY ETF.
PTN has a market cap of $15.30 million. This is considered a Sub-Micro Cap stock.
The top ETF exchange traded funds that PTN belongs to (by Net Assets): VXF, IWC.
PTN support price is $8.29 and resistance is $9.73 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PTN shares will trade within this expected range on the day.
